TY - JOUR
T1 - Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells
AU - Pan, Jingxuan
AU - Chen, Chun
AU - Jin, Yanli
AU - Fuentes-Mattei, Enrique
AU - Velazquez-Tores, Guermarie
AU - Benito, Juliana Maria
AU - Konopleva, Marina
AU - Andreeff, Michael
AU - Lee, Mong Hong
AU - Yeung, Sai Ching Jim
N1 - Funding Information:
No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manu- script. This study was also supported by grants from the follow- ing agencies: US. National Institute of Health (NIHRO1CA 089266, PI: M.H. Lee), Department of Defense, Breast Cancer Research Program (BCRP) of the Office of the Congressionally Supplemental Materials Directed Medical Research Programs (CDMRP) (Synergistic Supplemental materials may be found here: Idea Development Award BC062166, PI: S.C. Yeung and M.H. www.landesbioscience.com/journals/cc/article/20770 Lee), Susan G. Komen Foundation for Breast Cancer Research (Promise grant KG081048, PI: S.C. Yeung), National Natural Science Funds of China for Distinguished Young Scholars (grant 81025021, PI: J. Pan), National Basic Research Program of China (973 Program grant 2009CB825506, PI: J. Pan), the National Natural Science Fund of China (no. 90713036, PI: J. Pan; no. 30772367, PI: C. Chen), the Research Foundation of Education Bureau of Guangdong Province, China (Grant cxzd1103) to J. Pan, the Research Foundation of Guangzhou Bureau of Science and Technology, China (Grant to J. Pan), National High Technology Research and Development Program of China (863 Program grant 2008AA02Z420, PI: J. Pan) and the Fundamental Research Funds for Central Universities (PI: J. Pan). Enrique Fuentes-Mattei is supported by the MD Anderson Cancer Center Training Grant Program in Molecular Genetics (T32CA009299, PI: G. Lozano) and Guermarie Velazquez-Torres is supported by a National Cancer Institute grant minority supplement (parent grant R01CA089266, PI: M.H. Lee).
PY - 2012/6/15
Y1 - 2012/6/15
N2 - Hyperglycemia during hyper-CVAD chemotherapy is associated with poor outcomes of acute lymphoblastic leukemia (ALL) (Cancer 2004; 100:1179-85). The optimal clinical strategy to manage hyperglycemia during hyper-CVAD is unclear. To examine whether anti-diabetic pharmacotherapy can influence chemosensitivity of ALL cells, we examined the impacts of different anti-diabetic agents on ALL cell lines and patient samples. Pharmacologically achievable concentrations of insulin, aspart and glargine significantly increased the number of ALL cells and aspart and glargine did so at lower concentrations than human insulin. In contrast, metformin and rosiglitazone significantly decreased the cell number. Human insulin and analogs activated AKT/mTOR signaling and stimulated ALL cell proliferation (as measured by flow cytometric methods), but metformin and rosiglitazone blocked AKT/mTOR signaling and inhibited proliferation. Metformin 500 μM and rosiglitazone 10 μM were found to sensitize Reh cells to daunorubicin, while aspart, glargine and human insulin (all at 1.25 mIU/L) enhanced chemoresistance. Metformin and rosiglitazone enhanced daunorubicininduced apoptosis, while insulin, aspart and glargine antagonized daunorubicin-induced apoptosis. In addition, metformin increased etoposide-induced and L-asparaginase-induced apoptosis; rosiglitazone increased etoposideinduced and vincristine-induced apoptosis. In conclusion, our results suggest that use of insulins to control hyperglycemia in ALL patients may contribute to anthracycline chemoresistance, while metformin and thiazolidinediones may improve chemosensitivity to anthracycline as well as other chemotherapy drugs through their different impacts on AKT/mTOR signaling in leukemic cells. Our data suggest that the choice of anti-diabetic pharmacotherapy during chemotherapy may influence clinical outcomes in ALL.
AB - Hyperglycemia during hyper-CVAD chemotherapy is associated with poor outcomes of acute lymphoblastic leukemia (ALL) (Cancer 2004; 100:1179-85). The optimal clinical strategy to manage hyperglycemia during hyper-CVAD is unclear. To examine whether anti-diabetic pharmacotherapy can influence chemosensitivity of ALL cells, we examined the impacts of different anti-diabetic agents on ALL cell lines and patient samples. Pharmacologically achievable concentrations of insulin, aspart and glargine significantly increased the number of ALL cells and aspart and glargine did so at lower concentrations than human insulin. In contrast, metformin and rosiglitazone significantly decreased the cell number. Human insulin and analogs activated AKT/mTOR signaling and stimulated ALL cell proliferation (as measured by flow cytometric methods), but metformin and rosiglitazone blocked AKT/mTOR signaling and inhibited proliferation. Metformin 500 μM and rosiglitazone 10 μM were found to sensitize Reh cells to daunorubicin, while aspart, glargine and human insulin (all at 1.25 mIU/L) enhanced chemoresistance. Metformin and rosiglitazone enhanced daunorubicininduced apoptosis, while insulin, aspart and glargine antagonized daunorubicin-induced apoptosis. In addition, metformin increased etoposide-induced and L-asparaginase-induced apoptosis; rosiglitazone increased etoposideinduced and vincristine-induced apoptosis. In conclusion, our results suggest that use of insulins to control hyperglycemia in ALL patients may contribute to anthracycline chemoresistance, while metformin and thiazolidinediones may improve chemosensitivity to anthracycline as well as other chemotherapy drugs through their different impacts on AKT/mTOR signaling in leukemic cells. Our data suggest that the choice of anti-diabetic pharmacotherapy during chemotherapy may influence clinical outcomes in ALL.
KW - Acute lymphoblastic leukemia
KW - Chemoresistance
KW - Insulin
KW - Metformin
KW - Secretagogues
KW - Thiazolidinediones
UR - http://www.scopus.com/inward/record.url?scp=84862891813&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862891813&partnerID=8YFLogxK
U2 - 10.4161/cc.20770
DO - 10.4161/cc.20770
M3 - Article
C2 - 22659796
AN - SCOPUS:84862891813
SN - 1538-4101
VL - 11
SP - 2314
EP - 2326
JO - Cell Cycle
JF - Cell Cycle
IS - 12
ER -